Spyre Therapeutics, Inc. (SYRE): Shareholders' Equity
$715.24M
As of 2025-12-31
$1.10B
As of 2026-06-30
+142.3%
3-year compound annual growth
+38.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $715.24M | +38.1% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $517.80M | +181.4% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $184.02M | +265.8% | 2026-02-19, Balance as of period end |
| 2022-12-31 | $50.30M | -40.1% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $83.94M | -40.0% | 2024-11-18, Balance as of period end |
| 2020-12-31 | $139.83M | +132.7% | 2023-03-02, Balance as of period end |
| 2019-12-31 | $60.08M | -10.9% | 2022-03-08, Balance as of period end |
| 2018-12-31 | $67.43M | +34.0% | 2021-03-18, Balance as of period end |
| 2017-12-31 | $50.34M | -20.1% | 2020-02-24, Balance as of period end |
| 2016-12-31 | $62.97M | n/m | 2019-03-07, Balance as of period end |
| 2015-12-31 | -$22.21M | n/m | 2018-03-13, Balance as of period end |
| 2014-12-31 | -$11.47M | n/a | 2017-03-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $715.24M | +38.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare SYRE, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗